Drug · DIN 02498413
CLINIMIX E
8% AMINO ACIDS (BLEND D) WITH ELECTROLYTES IN 10% DEXTROSE WITH CALCIUM INJECTION
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 1, 2021; first marketed October 1, 2021.
- Drug Identification Number (DIN)
- 02498413
- Company (DIN owner)
- Baxter CorporationMississauga, Ontario, Canada
- Schedule
- Ethical
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Combinations B05BA10
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ALANINE | 1656 MG | 100 ML |
| L-ARGININE | 920 MG | 100 ML |
| GLYCINE | 824 MG | 100 ML |
| HISTIDINE | 384 MG | 100 ML |
| L-ISOLEUCINE | 480 MG | 100 ML |
| L-LEUCINE | 584 MG | 100 ML |
| L-LYSINE HYDROCHLORIDE | 464 MG | 100 ML |
| METHIONINE | 320 MG | 100 ML |
| L-PHENYLALANINE | 448 MG | 100 ML |
| L-PROLINE | 544 MG | 100 ML |
| SERINE | 400 MG | 100 ML |
| L-THREONINE | 336 MG | 100 ML |
| TRYPTOPHAN | 144 MG | 100 ML |
| L-TYROSINE | 32 MG | 100 ML |
| L-VALINE | 464 MG | 100 ML |
| DEXTROSE | 10 G | 100 ML |
| SODIUM CHLORIDE | 205 MG | 100 ML |
| POTASSIUM PHOSPHATE DIBASIC | 261 MG | 100 ML |
| MAGNESIUM CHLORIDE | 24 MG | 100 ML |
| CALCIUM CHLORIDE | 33 MG | 100 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 29, 2020: NOC 23678Supplement to a New Drug Submission (SNDS) · Additional strengths
Other DINs named CLINIMIX E
- DIN 02013967 · Marketed
- DIN 02014076 · Marketed
- DIN 02142384 · Marketed
- DIN 02498421 · Marketed
- DIN 02014025 · Cancelled Post Market
- DIN 02014041 · Cancelled Post Market
- DIN 02014068 · Cancelled Post Market
- DIN 02014084 · Cancelled Post Market
- DIN 02142341 · Cancelled Post Market
- DIN 02142376 · Cancelled Post Market